

- Accredited **GMP facility** for production of more than 10 different products (6 different INDs) with trained personnel (**cell therapy and gene therapy**).
- In house **centralized Clinical Trial Unit** with experience in **Phase I trials**.
- **Quality control/Quality assurance system** developed in house that controls: infrastructure, personnel, registries, equipment, process control, control of primary supplies, traceability, record of events, quality monitoring. System accredited and approved by the **Spanish Agency of Medical Products**.
- **Standard operating procedures (SOPs)** for all processes performed under GMP conditions.
- Large **animal facility** for both murine and large animal models allowing preclinical studies to test cell therapies.
- **Approaches:**
 - Clinical Trials with Mesenchymal Stem Cells (MSC) and other cell therapy products.
 - Clinical Trials with dendritic cells (DC) vaccines.

Clinical Trials Ongoing

Code	Abbreviated Title	Phase	EudraCT	IND Number	No. centers	No. patients Included
Mio/Reg/Perc	Percutaneous implant of autologous skeletal myoblast in chronic myocardial infarction.	II	2006-000679-14	06-014	2	36
-	Lymphoma Idiomatic Vaccine	--	-	-	14	58
DEND/GM	Vaccination with autologous DC in patients with glioblastoma multiforme.	II	2009-009879-35	09-033	1	32
CSM/CROH	Treatment of fistula in Chron's Disease: implant of autologous MSC from adipose tissue.	I/II	2009-009880-71	09-034	3	16
EPC/CIRR	Autologous endothelial progenitor cells from BM mononuclear cells for in liver cirrhosis.	I/II	2009-014278-16	10-012	1	14
CD-2009-01	Dendritic cells immunotherapy in hepatic metastases from colorectal cancer.	II	2008-007795-23	09-033	2	9
DEND/CM	Vaccination with autologous DC in Her2 negative breast cancer stages II-III.	II	2009-017402-36	09-033	2	22
LEA/VIT	Autologous melanocytes monolayer in amniotic membranes in stable vitiligo.	I/II	2009-017757-36	10-067/10-068	1	35
LFNK	Combined immunotherapy with autologous effector lymphocytes in non-Hodgkin lymphoma in rituximab maintenance therapy after response to first-line chemotherapy.	II	2009-017829-19	10-069	5	21
CDCC/2010	Vaccination with autologous DC in locally advanced high risk colon adenocarcinoma.	II	2010-024118-73	09-033	1	21
CD-AdNS3	Therapeutic vaccination in chronic hepatitis C with autologous DC transduced with recombinant adenovirus expressing hepatitis derived NS3 protein.	I/II	2010-024043-32	10-132	1	6
CMM/ART	Treatment of arthrosis with intra-articular injection of bone marrow MSC.	I/II	2009-017624-72	10-148/10-149	2	30
CMM-PRGF/ART	Treatment of arthrosis with intra-articular injection of bone marrow MSC and PRGF.	II	2011-006036-23	10-148/10-149	3	-
CD-2010-01	Immunotherapy with DC and hiltonol in patients with solid tumors.	II	2010-023139-40	09-033	1	7
CMM/FPI	Treatment of idiopathic pulmonary fibrosis with bone marrow MSC.	I	2011-006240-75	10-148/10-149	2	3
CMM/EM	Autologous transplant of MSC in multiple sclerosis.	I	2009-016442-74	10/037	1	9
CELLTRIMS	Injection of autologous bone marrow MSC in multiple sclerosis.	I/II	2010-024081-21	10/037	1	starting recruitment
FISPAC	Autologous SC from adipose tissue in complex perianal fistula in bowel inflammatory disease.	III	2012-001178-28	09-034	5	starting recruitment
LIVERADVANCE	Allogenic MSC in acute liver failure vs chronic.	III	2012-003900-11	10-148/10-149	1	starting recruitment
EMAOS	Amniotic membranes for treatment of severe dry eye vs. treatment with autologous serum eye drops.	III	2011-006287-50		1	starting recruitment

Treatments not included in Clinical Trials: compassionate use or established therapies.

Treatment	No. Patients Included
Bone marrow mononuclear cells for peripheral ischemia	10
Mesenchymal bone marrow stem cells for GVHD	11
Mesenchymal bone marrow stem cells for knee arthrosis	1
Mesenchymal bone marrow stem cells for multiple sclerosis	3
Mesenchymal bone marrow stem cells for necrosis of the hip	1
Mesenchymal bone marrow stem cells for Diabetes Mellitus type I	1
Mesenchymal stem cells derived from adipose tissue for decubitus ulcer	2
Epidermal layers enriched in melanocytes for treatment of vitiligo	59
Limbo-corneal cells for limbic deficiencies	12
Pulsed DC with tumor lysate for glioblastoma	15
Pulsed DC with tumor lysate for colon cancer	5
Pulsed DC with tumor lysate for breast cancer	15
Pulsed DC with tumor lysate for pediatric tumors	1
LF-NK for colon cancer	10